Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

transcreation

- PMLiVE

BMS, AbbVie’s Empliciti flunks trial in first-line multiple myeloma

Combination regimen didn't improve progression-free survival

Gamer

Could coronavirus turn us all into online gamers?

As businesses gauge the potential impact of coronavirus (COVID-19), with a sense of fear and pessimism causing a dampening of economic activity and suspension of the stock market, the healthcare...

Page & Page Health

- PMLiVE

US Department of Health and Human Services calls for coronavirus product proposals

Move will fast-track the development of potential treatments

- PMLiVE

UK government considers move into ‘delay’ phase of coronavirus response plan

Proposed emergency measures could include 'social distancing'

- PMLiVE

Shionogi makes buyout play for Tetra ahead of Alzheimer’s readout

Pivotal mid-stage trial results due later this month

- PMLiVE

FDA approves Recordati’s Cushing disease drug Isturisa

Important new treatment option for patients with rare disorder

- PMLiVE

Centre for Innovation in Regulatory Science awarded $1.09m Gates Foundation grant

Grant will help accelerate medicine registration in low/middle-income countries

- PMLiVE

FDA approves Allergan’s biodegradable glaucoma implant drug

Reduces intraocular pressure in glaucoma or ocular hypertension

- PMLiVE

Zydus Cadila scores first ever NASH approval, in India

Drug has already been approved for diabetes related conditions

AstraZeneca AZ

AstraZeneca’s Imfinzi fails first-line bladder cancer test

Unable to improve overall survival in advanced metastatic bladder cancer

- PMLiVE

Trevena gets second go at FDA approval for pain drug

FDA sets review completion date of 7 August 2020

13th Edition – Spring MEDAFFAIRS Leaders Forum

OPEN VIE (Amanda Pulfer, Strategic Director and Sergio Diaz, Patient Centred Outcomes Consultant) were delighted to speak at the Medical Affairs Leaders Forum yesterday.

OPEN Health

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links